Author | Elizabeth Mickiewicz, MD


Gemcitabine/Paclitaxel as First-Line Treatment of Advanced Breast Cancer

December 01, 2003

ByCarlos Delfino, MD|Graciela Caccia, MD|Luis Riva GonzÁles, MD|Elizabeth Mickiewicz, MD|Jeannette Rodger, MD|Luis Balbiani, MD|Daniel Flores Morales, MD|Alberto Zori Comba, MD|Celia Brosio, MD

Gemcitabine (Gemzar) and paclitaxel exhibit good activity and goodsafety profiles when used alone and together in the treatment of advancedbreast cancer. In a phase II trial, 45 patients with metastaticbreast cancer received gemcitabine at 1,200 mg/m2 on days 1 and 8 andpaclitaxel at 175 mg/m2 on day 1 every 21 days. Twenty-seven patients(60.0%) had prior adjuvant therapy. Objective response was observedin 30 patients (objective response rate 66.7%, 95% confidence interval[CI] = 52%–71%), including complete response in 10 (22.2%) and partialresponse in 20 (44.4%). Median duration of response was 18 months(95% CI = 11–26.7 months), median time to tumor progression for theentire population was 11 months (95% CI = 7.1–18.7 months), medianoverall survival was 19 months (95% CI = 17.3–21.7 months), and the1-year survival rate was 69%. Treatment was well tolerated, with grade3/4 toxicities being infrequent. Grade 3/4 leukopenia, neutropenia, andthrombocytopenia were each observed in six patients (13.3%). No patientwas discontinued from the study due to hematologic ornonhematologic toxicity. Thus, the gemcitabine/paclitaxel combinationshows promising activity and tolerability when used as first-line treatmentin advanced disease. The combination recently has been shownto be superior to paclitaxel alone as first-line treatment in anthracyclinepretreatedadvanced disease according to interim results of a phase IIItrial and it should be further evaluated in comparative trials in breastcancer.

Uracil/Tegafur Plus Oral Calcium Folinate in Advanced Breast Cancer

July 01, 1999

ByEduardo Richardet, MD, PhD|Cecilia Pedraza, MD|Elizabeth Mickiewicz, MD|Guillermo Lerzo, MD|Federico Coppola, MD|Alicia Elli, MD|Graciela Uranga, MD|Silvia Jovtis, MD|Mario Bruno, MD|Monica Ventriglia, MD|Maria Andrea Cuevas, MD|Ana Maria Alvarez, MD|Luis Alberto Suarez, MD|Luis Fein, MD

Uracil and tegafur (in a molar ratio of 4:1 [UFT]) has proven activity against breast cancer and is delivered in an easy-to-administer oral formulation. Orzel, which combines UFT with the oral biomodulator, calcium folinate, may